JPMorgan's upgrade of Biogen reflects confidence in the company's pipeline, particularly with the upcoming clinical data releases for several investigational drugs. Analyst Chris Schott highlighted the potential of felzartamab, which targets rare kidney diseases and could represent a market opportunity exceeding $2 billion.
The anticipated phase three data for this treatment is expected in the first half of 2027. Additionally, the ongoing trials for litifilimab, aimed at treating cutaneous lupus erythematosus, are promising due to the lack of approved therapies in this area, with results expected in late 2026.
Biogen's stock has already seen a 28% increase year to date, and with 26 out of 38 analysts rating it a buy or strong buy, the market sentiment appears favorable as the company approaches these critical data releases